FluoroPharma, a biopharmaceutical company engaged in discovery and development of imaging radiopharmaceuticals for use in cardiology and Alzheimer's disease, has appointed Thijs Spoor as the new CEO in conjunction with his appointment to its Board of Directors.  

Spoor has 15 years of international experience in the medical industry across a variety of roles including regulatory affairs, new product development and as the global brand head for nuclear cardiology at GE Healthcare and most recently as the chief financial officer of Sunstone BioSciences, according to the Boston-based FluoroPharma.